Oakstone Update in Urologic Oncology 2026

Updates for GU Cancer Care

Strengthen your clinical approach with the Update in Urologic Oncology. This high-yield continuing medical education course is an all-encompassing look at the full spectrum of genitourinary oncology. From new guidelines and recent trials to updated diagnostics and the latest therapeutic approaches, you’ll gain practical tools for board prep and knowledge you can use in your daily practice to improve care coordination, and optimize patient outcomes.

In this online video program, you’ll explore:

Comprehensive coverage of disease-specific diagnosis, treatment algorithms, and survivorship considerations.
Actionable updates on systemic therapies, immuno-oncology, biomarkers, and advanced imaging.
Expert insights into multidisciplinary care coordination, value-based care delivery, and patient-centered decision-making.
Practical tools to translate new evidence into clinical workflows and improve outcomes across diverse practice settings.

Date of Original Release: May 31, 2026
Estimated Time to Complete: 22.75 hours

Learning Objectives

Upon completion of this activity, you should be able to:

Interpret the latest NCCN/AUA guideline updates and pivotal trial data to optimize management of localized and advanced genitourinary malignancies.
Integrate imaging, genomic, molecular, and biomarker information into personalized diagnostic and treatment algorithms.
Formulate multidisciplinary treatment plans that appropriately sequence surgery, systemic therapy, radiation, and survivorship strategies.
Apply evidence-based multidisciplinary and survivorship strategies to improve quality and coordination of care in genitourinary oncology
Evaluate emerging therapies, clinical-trial data, and evolving standards of care relevant to genitourinary oncology practice.
Intended Audience

This activity was designed for urologists, urologic oncologists, and medical oncologists.

+ Topics:

Understanding the Global Epidemiology and Burden of Genitourinary Cancers – Aaron Laviana, MD, MBA

Clinical Trial Design and Interpretation for the Busy Surgeon – Kristian Stensland, MD, MPH, MS

Contemporary PSA-Based Screening for Prostate Cancer – Evidence, Controversies, and Risk-Adapted Approach – Udit Singhal, MD

Prostate Biopsy – Techniques, Pitfalls, and Future Directions – Kara Watts, MD

Genomic Classifiers Part 1 – Prostate Cancer Screening Risk Assessment – Randy A. Vince, Jr., MD, MS

Genomic Classifiers Part 2 – Prostate Cancer Risk Stratification – Randy A. Vince, Jr., MD, MS

Active Surveillance in Prostate Cancer – Kristen R. Scarpato, MD, MPH

Robotic-Assisted Radical Prostatectomy – Novel Techniques – Keith J. Kowalczyk, MD

Radiation Therapy for Prostate Cancer – Low and Intermediate Risk Categories – Khush Singh Aujla, MD, MHA

Radiation Therapy for Prostate Cancer – High-Risk Localized and Locally Advanced Categories – Khush Singh Aujla, MD, MHA

Focal Therapy for Prostate Cancer – Kara Watts, MD

Principles of Prostate Cancer Survivorship after Radical Prostatectomy – Erectile Dysfunction and Urinary Incontinence – Niels V. Johnsen, MD, MPH, FACS

ligometastatic and Biochemical Recurrence of Prostate Cancer – Mohummad Minhaj Siddiqui, MD FACS

Management of Advanced Prostate Cancer for the Urologist – Part 1 – De novo Locally Advanced Systemic Therapy – Catherine Fahey, MD, PhD

Management of Advanced Prostate Cancer for the Urologist – Part 2 – De novo Metastatic Systemic Therapy – Catherine Fahey, MD, PhD

Managing Treatment-Related Adverse Effects, Sexual Health, and Survivorship after Prostate Cancer Treatment – Cameron J. Britton, MD

Contemporary Workup of Microscopic and Gross Hematuria – Mary Beth Westerman, MD

Non-Muscle-Invasive Bladder Cancer Part 1 – Diagnosis and Risk Stratification – Helen Y. Hougen, MD

Non-Muscle-Invasive Bladder Cancer Part 2 – Treatments – Helen Y. Hougen, MD

Neo-Adjuvant Chemotherapy Prior to Radical Cystectomy for Muscle Invasive Bladder Cancer – Parminder Singh, MD

Adjuvant Therapy for Muscle – Invasive Bladder Cancer – Parminder Singh, MD

Radical Cystectomy for Muscle-Invasive Bladder Cancer – Surgical Approaches and Urinary Diversions – Laura Bukavina, MD, MPH, MSc

Trimodality Bladder-Preservation Protocols for MIBC – Wesley Yip, MD

Upper-Tract Urothelial Carcinoma – Diagnosis and Treatment – Amy Luckenbaugh, MD, FACS

Novel Imaging Strategies in Renal Mass Staging and Detection – Ava Saidian, MD

Management of Small Renal Masses – Daniel D. Shapiro, MD, FACS

Surgical Approaches for Renal Masses – Overview of Open Surgery, and Anatomical Considerations – Kelvin A. Moses, MD, PhD, FACS

Small Renal Masses – Overview of Robotic Approaches – Daniel D. Joyce, MD, MS

Advanced RCC – Venous Tumor Thrombi and Cytoreductive Nephrectomy – Vidit Sharma, MD, MS

Renal Cell Carcinoma – Implications for Radiation Therapy – Dakim Gaines, MD, PhD

The Systemic Therapy Landscape for RCC – Katy Beckermann, MD, PhD

Non-Clear-Cell Renal Masses and Hereditary RCC Syndromes – Allison May, MD

Early-Stage Germ-Cell Tumors – Management Approaches – Daniel D. Joyce, MD, MS

Metastatic Germ-Cell Cancer – Management Approaches – Nirmish Singla, MD, MSCS, FACS

Penile Cancer Part 1 – Organ Confined Disease – Reza Nabavizadeh, MD

Penile Cancer Part 2 – Adavanced Disease – Reza Nabavizadeh, MD

Enhanced Recovery After Surgery – Saum B. Ghodoussipour, MD

Palliative and End-of-Life Care – Integrating Early with Curative-Intent Pathways – Kristen R. Scarpato, MD, MPH

Artificial Intelligence Applications for GU Cancers – Abhinav Khanna, MD

Optimizing Sexual Health in Women Undergoing Radical Cystectomy – Ariana L. Smith, MD

Pediatric Urologic Oncology – Leslie M. Peard, MD

Frailty Assessments in GU Cancer Patients – Logan Briggs, MD

Diagnosis and Management of Benign Adrenal Lesions – Marshall Strother, MD

Malignant Adrenal Masses for the Urologist – Jacob Tallman, MD

Smoking Cessation in Genitourinary Cancer Care – Marc Bjurlin, DO, MSc

Optimizing Performance and Efficiency in Robotic-Assisted Procedures – Janet Kukreja, MD, MPH, FACS